ClinicalTrials.gg
Not yet recruitingNCT07893379Updated Oct 26, 2026

joyVision: The Superiority of Co-design in the Development of a Serious Game for Children With Cerebral Visual Impairment

An interventional study of serious game in Cerebral Visual Impairment, sponsored by Universitaire Ziekenhuizen KU Leuven. Not yet recruiting. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Treatment

Updated Oct 26, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
3 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the superiority of the through codesign redesigned game joyVision over the iVision game for children with a cognitive age between 3 and 12 with CVI.

The main question it aims to answer is:

- Does the joyVision game have a better adherence than the iVision game

Participants will play with both Ivision and joyVision for one month, in a randomized AB/BA sequence.

02

Conditions studied

  • Cerebral Visual Impairment

Browse trials for

03

In context

Blindness, Cortical

33 studies on the registry are indexed under Blindness, Cortical; 28 are open to participants now.

This study's planned enrollment of 34 is below the median of 60 across 22 interventional studies indexed under Blindness, Cortical.

Browse Blindness, Cortical studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 959 studies on the registry; 263 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of CVI
  • performance age between 3 and 12 years
  • sufficient visual acuity (>0.2 on the decimal scale)
  • sufficient manual dexterity and coordination (Gross Motor Function Classification System (GMFCS) I-IV, Manual Ability Classification System (MACS) I-III)
  • understanding the verbal instructions, indicated by the guardian of the child

Exclusion criteria

Exclusion Criteria:

  • uncontrolled epilepsy (or taking Vigabatrin)
  • severe behavioural problems or autism interfering with participation
  • oculomotor apraxia
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    iVision/joyVision

    The children will first play iVision for a month and then joyVision for a month

    Other: serious game

  • Experimental
    joyVision/iVision

    The children will first play joyVision for a month and then iVision for a month

    Other: serious game

Interventions

  • Otherserious game

    the playing of a serious game multiple times a week for a month

    Also known as: iVision, joyVision

06

What researchers measure

Primary outcomes

  1. play frequency

    Time frame: immediately after the intervention

  2. play duration

    Time frame: immediately after the intervention

Secondary outcomes

  1. duration to complete each task

    Time frame: immediately after the intervention

  2. number of errors made for each task

    Time frame: immediately after the intervention

  3. number of completed tasks

    Time frame: immediately after the intervention

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2027; primary completion for Jun 2028, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Oct 26, 2026
StartEst.
Jun 2027
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07893379
Responsible party
Sponsor
First posted
Oct 26, 2026
Start date
Jun 2027 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 26, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion